![]() ![]() If a person is infected with smallpox and they are in close contact with others, the virus can spread quickly. The virus can also be spread through other body fluids and contaminated clothing or bed linen. The smallpox virus is spread through saliva and droplets from the respiratory tract or by direct or indirect contact with the virus as it is shed from skin lesions. A person infected with smallpox typically develops a rash characterized by raised pocks on the face and body. ![]() Smallpox, which is caused by the variola virus, emerged in human populations thousands of years ago and is a highly contagious and often fatal infectious disease. The availability of this vaccine in the SNS will help ensure that the vaccine is accessible in the U.S. This vaccine is also part of the Strategic National Stockpile (SNS), the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency that is severe enough to cause local supplies to be depleted. Jynneos will be available for those determined to be at high risk of either smallpox or monkeypox infection. government’s commitment to preparedness through support for the development of safe and effective vaccines, therapeutics, and other medical countermeasures.” “Therefore, although naturally occurring smallpox disease is no longer a global threat, the intentional release of this highly contagious virus could have a devastating effect. and, as a result, a large proportion of the U.S., as well as the global population has no immunity,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. Routine vaccination of the American public was stopped in 1972 after the disease was eradicated in the U.S. “Following the global Smallpox Eradication Program, the World Health Organization certified the eradication of naturally occurring smallpox disease in 1980. This is the only currently FDA-approved vaccine for the prevention of monkeypox disease. Food and Drug Administration announced today the approval of Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating, for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. For Immediate Release: September 24, 2019
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |